Company Information
Industry 制造业
Company Introduction 浙江东亚药业股份有限公司,成立于1998年,总部位于浙江省台州市,现有员工1300多人,总资产达13亿元。先后获得“国家高新技术企业”、“浙江省专利示范企业”、“台州市管理创新十强企业”等称号。并建有省级研究院、省级企业技术中心,曾多次承担国家火炬计划项目,现已申请国家发明专利30余项,已获国家发明专利授权27项,PCT国际专利1项。 东亚在浙江三门、浙江临海、江西九江建有一体化的制药基地,主营心脑血管、抗老年失智失能、消化系统、糖尿病神经病变、抗病原微生物(包括β-内酰胺类抗生素、碳青霉烯类半合成抗生素和合成抗菌、抗真菌、抗病毒)感染、中枢神经系统等领域的原料药及中间体。公司多个产品通过新版CGMP认证、欧盟(EDQM)认证、日本厚生省(PMDA)认证。与欧美、东南亚等十多个国家和地区的客户建立了长期合作关系,产品销售网络遍及全球50多个国家和地区。 东亚在上海国际医学园区设有现代化的研发中心,并建立了以博士、硕士为主的科研团队,专业从事前沿信息和技术的研究和研发,为公司的持续发展的市场竞争提供平台。 公司本着“品质责任、呵护生命;至诚守信、致力发展;健康使命,科技护航;承诺社会,感恩回馈”的方针政策,做以善为本,方能渊源流长的“善渊”药企。
Main Business 化学原料药、医药中间体的研发、生产和销售,主导产品涵盖抗细菌类药物(β-内酰胺类和喹诺酮类)、抗胆碱和合成解痉药物(马来酸曲美布汀)、皮肤用抗真菌药物等多个用药领域。
Legal Representative 池骋
Top Executives
董事长:池骋
董事:王胜,钱江犁,夏道敏,池骋
独立董事:綦方中,崔孙良,冯燕
Top 5 Shareholder
Shareholder name Nature Holding Date
池正明流通A股41.06%30/09/2024
池骋流通A股6.79%30/09/2024
沈立刚流通A股2.90%30/09/2024
台州市瑞康投资合伙企业(有限合伙)流通A股2.18%30/09/2024
陈东辉流通A股1.09%30/09/2024
Company Secretary 周剑波
Solicitors 上海市通力律师事务所
Auditors 中汇会计师事务所(特殊普通合伙)
Tel No 0576-89185661;0576-84039635
Fax No 0576-84285399
Website www.eapharm.net
Email dyzqb@eapharm.net
Company Address
Register: 浙江省台州市三门县浦坝港镇沿海工业城
Office: 浙江省台州市黄岩区劳动北路118号总商会大厦23层
Listing Date 25/11/2020
Shares Capital
Shares Capital: 114,753,580
Total A Share: 114,753,580
Listed A Share: 114,753,580
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.070
DPS(RMB)* ¥ 0.327
NBV Per Share(RMB)* ¥ 16.712
Market Capitalization(RMB) 2.207B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.